AAPGAscentage Pharma Group Inc.Signing up patients
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 123 (planned)
- Started
- Aug 31, 2020
- Main results expected
- Oct 20, 2024
- Fully finished
- Dec 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse events of APG-2575 single agent
Measured over: Up to 6 cycles (each cycle is 28 days).
Objective Response Rate (ORR) of APG-2575 single agent
Measured over: Up to 6 cycles (each cycle is 28 days).
Dose Limiting Toxicities (DLT) of combination therapy
Measured over: 28 days.
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)
Measured over: 28 days.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-10-20, no fading
Raw record changes
- none yet
Trial ID NCT04494503 · record last updated 2025-04-16 · checked 2026-11-09 15:42 UTC